期刊
FRONTIERS IN MICROBIOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2021.651403
关键词
COVID-19; severe acute respiratory syndrome-related coronavirus 2; SARS-CoV-2; repurposing; malaria; mefloquine; coronavirus
类别
资金
- Agency for Medical Research and Development (AMED) emerging/re-emerging infectious diseases project [JP19fk0108111, JP19fk0108156, JP20fk0108179, JP20fk0108274, JP20fk0108294, JP20fk0108411, JP20fk0108511]
- Japan Society for the Promotion of Science KAKENHI [JP20H03499]
- JST MIRAI program
- Moonshot RD [JPMJMS2021, JPMJMS2025]
Mefloquine, an anti-malarial drug, demonstrated higher anti-SARS-CoV-2 activity than Hydroxychloroquine, inhibiting viral entry to target cells and showing synergistic antiviral activity when combined with other drugs. Mathematical modeling predicted that standard dosage of Mefloquine could reduce viral load and shorten the time until virus elimination in patients.
Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we screened approved anti-parasitic/anti-protozoal drugs and identified an anti-malarial drug, Mefloquine, which showed the highest anti-SARS-CoV-2 activity among the tested compounds. Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 mu M, IC90 = 2.31 mu M, and IC99 = 4.39 mu M in VeroE6/TMPRSS2 cells. Mefloquine inhibited viral entry after viral attachment to the target cell. Combined treatment with Mefloquine and Nelfinavir, a replication inhibitor, showed synergistic antiviral activity. Our mathematical modeling based on the drug concentration in the lung predicted that Mefloquine administration at a standard treatment dosage could decline viral dynamics in patients, reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.1 days. These data cumulatively underscore Mefloquine as an anti-SARS-CoV-2 entry inhibitor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据